Pulse Biosciences, Inc. , developer of the novel nPulsetm technology using its proprietary Nanosecond Pulsed Field Ablationtm (nanosecond PFA or nsPFAtm) energy, today announced first patient ...
Immunotherapy given during and after chemoradiation did not improve survival for study participants with limited-stage, small-cell lung cancer (SCLC ...
22h
Genomic Testing Cooperative Opens Houston Laboratory, Expanding National Precision Oncology Network
Genomic Testing Cooperative (GTC), a leading provider of integrated DNA and RNA next-generation sequencing (NGS) solutions ...
HAYWARD, Calif., March 12, 2026--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results